These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35875991)

  • 1. Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis.
    Papp KA; Thoning H; Gerdes S; Megna M; Brandi H; Jablonski Bernasconi MY; Yélamos O
    J Dermatolog Treat; 2022 Nov; 33(7):3005-3013. PubMed ID: 35875991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis.
    Wu JJ; Hansen JB; Patel DS; Nyholm N; Veverka KA; Swensen AR
    J Med Econ; 2020 Jun; 23(6):641-649. PubMed ID: 31985301
    [No Abstract]   [Full Text] [Related]  

  • 3. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
    Bewley AP; Shear NH; Calzavara-Pinton PG; Hansen JB; Nyeland ME; Signorovitch J
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1107-1115. PubMed ID: 30472749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
    Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Olesen M; Østerdal ML; Stein Gold L
    J Drugs Dermatol; 2015 Dec; 14(12):1468-77. PubMed ID: 26659941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis.
    Adam DN; Jablonski Bernasconi MY; Thoning H; Wu JJ
    Dermatol Ther (Heidelb); 2022 Nov; 12(11):2589-2600. PubMed ID: 36223060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30
    Pinter A; Gold LS; Reich A; Green LJ; Praestegaard M; Selmer J; Armstrong AW; Danø A; Dhawan S; Galván J; Stallknecht SE; Trebbien P; Augustin M
    J Eur Acad Dermatol Venereol; 2023 Jan; 37 Suppl 1():14-19. PubMed ID: 36546465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis.
    Bewley A; Barker E; Baker H; Green W; Avey B; Pi-Blanque A; Galván J; Trebbien P; Praestegaard M
    J Dermatolog Treat; 2022 Dec; 33(8):3191-3198. PubMed ID: 36036596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies.
    Stein Gold L; Lebwohl M; Menter A; Villumsen J; Rosen M; Koo J
    J Drugs Dermatol; 2016 Aug; 15(8):951-7. PubMed ID: 27537995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease.
    Pink AE; Jalili A; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D; Torpet M; Jensen KL; Segaert S
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1116-1123. PubMed ID: 30916417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.
    Paul C; Leonardi C; Menter A; Reich K; Gold LS; Warren RB; Møller A; Lebwohl M
    Am J Clin Dermatol; 2017 Jun; 18(3):405-411. PubMed ID: 28236223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation.
    Gallo L; Megna M; Cirillo T; Caterino P; Lodi G; Mozzillo R; Dente V; Balato A
    J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1312-1315. PubMed ID: 30767288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam is Effective, Independent of Body Mass Index and the Extent and Severity of Psoriasis.
    Stein Gold L; Villumsen J; Rosen M
    Dermatol Ther (Heidelb); 2016 Dec; 6(4):667-673. PubMed ID: 27714595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, quality of life, and treatment satisfaction: an indirect comparison of calcipotriol/betamethasone dipropionate cream versus foam for treatment of psoriasis.
    Reich A; Selmer J; Galván J; Trebbien P; Pi-Blanque A; Danø A; Stallknecht SE; Bewley A
    Curr Med Res Opin; 2022 Sep; 38(9):1521-1529. PubMed ID: 35575759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.
    Koo J; Tyring S; Werschler WP; Bruce S; Olesen M; Villumsen J; Bagel J
    J Dermatolog Treat; 2016; 27(2):120-7. PubMed ID: 26444907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.
    Queille-Roussel C; Olesen M; Villumsen J; Lacour JP
    Clin Drug Investig; 2015 Apr; 35(4):239-45. PubMed ID: 25708531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis.
    Foley P; Garrett S; Ryttig L
    Curr Med Res Opin; 2018 Jul; 34(7):1277-1283. PubMed ID: 29336190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis.
    Kircik LH; Schlesinger TE; Tanghetti E
    J Drugs Dermatol; 2020 Sep; 19(9):874-880. PubMed ID: 33026749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis treatments.
    Queille-Roussel C; Bang B; Clonier F; Lacour JP
    J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):1951-1956. PubMed ID: 27306589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis.
    Pinter A; Reich A; Arenberger P; Gold LS; Armstrong A; Iversen L; Praestegaard M; Augustin M
    J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2327-2335. PubMed ID: 37432045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study.
    Paul C; Stein Gold L; Cambazard F; Kalb RE; Lowson D; Bang B; Griffiths CE
    J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):119-126. PubMed ID: 27531752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.